Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Genomic Valley Biotech's Days Payable or its related term are showing as below:
During the past 12 years, Genomic Valley Biotech's highest Days Payable was 7208.75. The lowest was 37.36. And the median was 140.73.
BOM:539206's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84 * Ranked among companies with meaningful Days Payable only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:539206 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Genomic Valley Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomic Valley Biotech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genomic Valley Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Genomic Valley Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Genomic Valley Biotech's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomic Valley Biotech (BOM:539206) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genomic Valley Biotech and its competitors. Over the past decade, Genomic Valley Biotech's Days Payable has ranged from 37.36 to 7,208.75. According to the industry distribution chart, Genomic Valley Biotech ranks #999999 out of 703 companies in the Biotechnology industry.
Is Genomic Valley Biotech's Days Payable too high?
Genomic Valley Biotech's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 37.36 to a high of 7,208.75. Based on the distribution chart, Genomic Valley Biotech ranks #999999 out of 703 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genomic Valley Biotech has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genomic Valley Biotech's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genomic Valley Biotech ranks #999999 out of 703 companies for Days Payable. This places Genomic Valley Biotech in the lower half of its industry. The industry median Days Payable is 112.84. Historically, Genomic Valley Biotech's own Days Payable has ranged from 37.36 to 7,208.75 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genomic Valley Biotech and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomic Valley Biotech's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomic Valley Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genomic Valley Biotech (BOM:539206) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹12.92, compared to a current price of ₹29.29 — trading 126.7% above its estimated fair value. The current Days Payable is 0.00. Genomic Valley Biotech's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Genomic Valley Biotech (BOM:539206), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomic Valley Biotech (BOM:539206) Overvalued in 2026?
Based on GuruFocus' analysis, Genomic Valley Biotech stock appears to be overvalued.
The current stock price of ₹29.29 is trading 126.7% above its estimated GF Value™ of ₹12.92.
GuruFocus considers Genomic Valley Biotech to be Significantly Overvalued.
Key valuation signals for BOM:539206:
Days Payable: 0.00
GF Value™: ₹12.92 vs. price of ₹29.29 (126.7% above fair value)
No single metric tells the full story. See the BOM:539206 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomic Valley Biotech Ltd is an India-based biotechnology company operating in the fields of genomics, molecular diagnostics, and AI-driven healthcare. The Company provides Next-Generation Sequencing (NGS) based diagnostic services, oncology diagnostics, personalized healthcare solutions, genetic disease risk assessment, community genomic screening, and research process outsourcing services. Its business is mainly segmented into diagnostic services and research services, with a focus on genomics, bioinformatics, and AI-enabled data analysis. The Company operates mainly in India, while also serving international researchers and collaborators.
57GF Score
Get the complete analysis for BOM:539206
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539206 has been successfully added to your 
